Literature DB >> 647983

Hyperprolactinaemia and impotence.

S Franks, H S Jacobs, N Martin, J D Nabarro.   

Abstract

Clinical, laboratory and radiological findings were evaluated in twenty-nine men who had raised serum prolactin concentrations and pituitary tumours. Twenty-one had functionless pituitary tumours ('prolactinomas') and eight had acromegaly. Supraseller extension was detected in twenty of the twenty-six men who had lumbar airencephalography. Three patients were studied before, sixteen before and after and ten only after pituitary ablative therapy. Seventeen of these men complained of complete lack of libido and impotence and six had impaired libido and sexual potency; only six patients in this series denied reproductive symptoms. Thirteen of the impotent subjects had small soft testes, ten reduced facial and body hair and three had marked gynaecomastia. No features of hypogonadism were noted in the six patients without reproductive symptoms and none of the patients had galactorrhoea. Serum prolactin concentrations were higher and serum testosterone concentrations lower in the impotent men compared with those with normal sexual potency. Serum LH and FSH (both basal and in response to LHRH) oestradiol and oestrone concentrations were not different between the two groups and, except in those with post-operative hypopituitarism, were within the normal range. Following successful lowering of prolactin concentrations by surgery or bromocripitine or both, serum testosterone rose and potency returned; by contrast failure to lower prolactin concentrations was associated with persistent impotence and hypogonadism. The endocrine profile of low serum testosterone concentrations with gonadotrophins which had not risen into the range usually seen in primary hypogonadism (together with the parallel increase of LH and testosterone in one patient studied sequentially during treatment which suppressed prolactin levels to normal), suggested that the impaired gonadal function was caused by a prolactin-mediated disturbance of hypothalamic-pituitary function.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647983     DOI: 10.1111/j.1365-2265.1978.tb02770.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  Gynecomastia induced by treatment with tandospirone, a 5-HT1A agonist.

Authors:  Y Kaneda; T Morimoto; A Fujii
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

2.  Male sexual dysfunction during treatment with cimetidine.

Authors:  N R Peden; J M Cargill; M C Browning; J H Saunders; K G Wormsley
Journal:  Br Med J       Date:  1979-03-10

Review 3.  Impotence: diagnosis and management of male erectile dysfunction.

Authors:  R S Kirby
Journal:  BMJ       Date:  1994-04-09

4.  The Japanese plasma cell dyscrasia syndrome: case report and theory of pathogenesis.

Authors:  M J Tobin; M X Fitzgerald
Journal:  Postgrad Med J       Date:  1982-12       Impact factor: 2.401

5.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

Review 6.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

7.  Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.

Authors:  L Rossi; U Bonuccelli; G Marcacci; A Bindi; G De Scisciolo; R Arena
Journal:  Ital J Neurol Sci       Date:  1983-06

8.  Plasma prolactin and estradiol during sleep in impotent men and normal controls.

Authors:  R C Schiavi; C Fisher; D White; J Thornton
Journal:  Arch Sex Behav       Date:  1986-08

9.  Effects of sulpiride induced hyperprolactinemia on testosterone secretion and metabolism before and after HCG in normal men.

Authors:  G P Bernini; M Gasperi; F Franchi; M Luisi
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256

Review 10.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.